For patients considering Human Microbiota Therapy

If you are considering HMT therapy as a patient, you may inquire with your supervising medical physician or contact our medical advisory staff at the Hong Kong Digestive Health Centre.

To book an appointment please fill out the form, or if the form does not display, please click here or call us +852 3619 5220 / email us: / WhatsApp: +852 5190 6282

Human Microbiota Therapy (HMT) has been used as a therapy for gastrointestinal diseases for decades, but only recently has become the object of focused study and application. Currently, fecal microbiota transplant or HMT is being used in dozens of countries around the world, including the US, UK, Australia and Israel, as a treatment for Clostridium Difficile infection (CDI). FMT is generally effective more than 90 percent of the time as a treatment for CDI. In the US, the FDA has allowed clinicians to provide FMT to recurrent C. difficile patients.

Currently, FMT is also being researched as a treatment for many gastrointestinal related diseases, including Inflammatory Bowel Disease (Crohn’s Disease, Ulcerative Colitis), Irritable Bowel Syndrome, and other chronic digestive diseases. Medical clinics and FMT treatment centers in the UK and Australia have reported cases of successfully treating these diseases and conditions.

The following have been published medical studies results for various conditions:

C. Difficile – 90%+ resolution

Ulcerative Colitis – 27% resolution and 59% benefit

Irritable Bowel Syndrome (IBS) – 65% benefit

The goal is to restore the gut bacteria imbalance – dysbiosis – therefore conditions which stem from or correlate to dysbiosis will respond best.

Gut related conditions

  • C difficile infection
  • Ulcerative Colitis
  • Crohn’s disease
  • IBS-D
  • IBS-C (if SIBO is excluded)
  • IBS-M
  • Post-infectious IBS seems to be strongly linked with dysbiosis
  • Functional Gastro-Intestinal Disorders (FGID)
    • Chronic constipation
    • Chronic diarrhea

Ex-gut conditions

As a policy, the Asia Microbiota Bank does not endorse or support the use of Human Microbiota Transplant for the treatment of ex-gut (non-gut) related conditions. AMB does support the treatment of gut conditions in patients which also have a related condition or gut-mediated condition.

Conditions which have reported benefit in patients who have undergone HMT:

  • Autism Spectrum Disorder
  • Skin-related: Atopic dermatitis, eczema, psoriasis
  • Multiple sclerosis
  • Metabolic disorder, including diabetes
  • Chronic fatigue syndrome
  • Parkinson’s disease
  • Hepatic encephalopathy

[1] Choi HH, Cho Y-S. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clinical Endoscopy. 2016;49(3):257-265. (

[2] Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Singh UP, ed. PLoS ONE. 2016;11(6): e0157259. (

[3] Kang D-W, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5:10. doi:10.1186/s40168-016-0225-7. ( (80% reduction in ASD GI Symptoms and 24% improvement in Childhood Autism Rating Scale (CARS), which rates core ASD symptoms after 8 weeks of no treatment)

[4] Li N, Tian H, Ma C, Ding C, Ge X, Gu L, Zhang X, Yang B, Hua Y, Zhu Y, Zhou Y. Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Jan 25;20(1):40-46.

[5] Paramsothy, Sudarshan et al.  Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet, Volume 389 , Issue 10075 , 1218 – 1228

*The research above is a small sample size and representative of a single example of the efficacy of HMT. Previous success rates in clinical research are no guarantee of future remission.